A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After First Line Chemotherapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Avelumab (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- Acronyms AveNEC
- 22 Nov 2017 Planned End Date changed from 21 May 2023 to 1 Jan 2024.
- 22 Nov 2017 Status changed from recruiting to not yet recruiting.
- 29 Aug 2017 New trial record